Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 (SGLT1) and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: The inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North American adults with T1D to placebo (n = 268), sotagliflozin 200 mg (n = 263), or sotagliflozin 400 mg (n = 262) after 6 weeks of insulin optimization. The primary end point was HbA1c change from baseline at 24 weeks. HbA1c, weight, and safety were also assessed through 52 weeks. RESULTS: From a mean baseline of 7.57%, placebo-adjusted HbA1c reductions were 0.36% and 0.41% with sotagliflozin 200 and 400 mg, respectively, at 24 weeks and 0.25% and 0.31% at 52 weeks (all P < 0.001). Among patients with a baseline HbA1c ≥7.0%, an HbA1c <7% was achieved by 15.7%, 27.2%, and 40.3% of patients receiving placebo, sotagliflozin 200 mg, and sotagliflozin 400 mg, respectively (P ≤ 0.003 vs. placebo) at 24 weeks. At 52 weeks, mean treatment differences between sotagliflozin 400 mg and placebo were −1.08 mmol/L for fasting plasma glucose, −4.32 kg for weight, and −15.63% for bolus insulin dose and −11.87% for basal insulin dose (all P < 0.001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly by 2.5 points with sotagliflozin versus placebo (P < 0.001) at 24 weeks. Genital mycotic infections and diarrhea occurred more frequently with sotagliflozin. Adjudicated diabetic ketoacidosis (DKA) occurred in 9 (3.4%) and 11 (4.2%) patients receiving sotagliflozin 200 and 400 mg, respectively, and in 1 (0.4%) receiving placebo. Severe hypoglycemia occurred in 17 (6.5%) patients from each sotagliflozin group and 26 (9.7%) patients receiving placebo. CONCLUSIONS: In a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was associated with sustained HbA1c reduction, weight loss, lower insulin dose, fewer episodes of severe hypoglycemia, improved patient-reported outcomes, and more DKA relative to placebo (ClinicalTrials.gov, NCT02384941).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there is preliminary evidence that in select individuals with type 1 diabetes and excess adiposity, newer pharmacotherapy (i.e., glucagonlike peptide 1 receptor agonists or sodium -glucose cotransporter 2 inhibitors) (195,196) can decrease body weight and improve glycemia, though they are currently not indicated.”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [195]
Citations
Cites
Assessing Psychosocial Distress in Diabetes
Polonsky, W. H., Fisher, L., Earles, J., Dudl, R. J., Lees, J., Mullan, J., & Jackson, R. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.626 · Cited by 1,575 · cited 4×
“At week 24, sotagliflozin-treated patient scores on the DDS2 decreased by 0.7 (20.9 to20.”
BackgroundInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849 · cited 1×
“has emerged as the major clinical concern around SGLT inhibition in T1D (17,18).”
BackgroundSelf-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602 · cited 1×
“have been largely limited to insulin formulation and delivery innovations (1,5,6).”
BackgroundGarg, S. K., Weinzimer, S. A., Tamborlane, W. V., Buckingham, B. A., Bode, B. W., Bailey, T. S., Brazg, R. L., Ilany, J., Slover, R. H., Anderson, S. M., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0421 · Cited by 585 · cited 1×
“have been largely limited to insulin formulation and delivery innovations (1,5,6).”
BackgroundSelf-citationWeissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Effects of sotagliflozin added to insulin in patients with type 1 diabetes
Garg, S. K., Henry, R. R., Banks, P., Buse, J. B., Davies, M. J., Fulcher, G. R., Pozzilli, P., Gesty-Palmer, D., Lapuerta, P., Simó, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708337 · Cited by 417 · cited 2×
“incidence of DKA in patients with T1D (14).”
BackgroundSelf-citationAgiostratidou, G., Anhalt, H., Ball, D., Blonde, L., Gourgari, E., Harriman, K. N., Kowalski, A. J., Madden, P., McAuliffe-Fogarty, A. H., McElwee-Malloy, M., et al. (2017) · Diabetes Care · doi:10.2337/dc17-1624 · Cited by 397
Self-citation
Research works printed but not linked: 1
- Bradley, 1994, The Diabetes Treatment Satisfaction Questionnaire: DTSQ, 111
Cited by
Items 201–234 of 234
Practical ways to achieve targets in diabetes care conference
Biba, U., Teng, R. W., Kurian, M. J., & Close, K. L. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12971
Jermendy, G. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.9
SGLT inhibitors for type 1 diabetes: a finely balanced matter?
Morris, D. (2020) · Independent Nurse · doi:10.12968/indn.2020.4.14 · Cited by 1
SGLT inhibitors for type 1 diabetes
Das, G. C. (2020) · Practical Diabetes · doi:10.1002/pdi.2273
Zhou, X., Zhou, Y., Li, X., & Xiao, X. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14138 · Cited by 1
Kahkoska, A. R. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/pmkd-k264
Tang, X., Yan, X., Zhou, H., Huang, G., Niu, X., Jiang, H., Su, H., Yang, X., Li, X., & Zhou, Z. (2020) · Research Square · doi:10.21203/rs.3.rs-130639/v1
Veneti, S., & Τζιόμαλος, Κ. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967931
“a similar rate with placebo in the inTandem1 study [22,23].”
BackgroundResultInfluentialPeters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · doi:10.2337/figshare.12824342
Self-citationPeters, A. L., McGuire, D. K., Danne, T., Kushner, J. A., Rodbard, H. W., Dhatariya, K., Sawhney, S., Banks, P. L., Jiang, W., Davies, M. J., et al. (2020) · doi:10.2337/figshare.12824342.v1
Self-citationUSE OF SGLT2 INHIBITORS IN TYPE 1 DIABETES: EXPERIENCE FROM A PORTUGUESE TERTIARY CENTER
Lavrador, M., Araújo, B., Melo, M., Barros, L., & Paiva, I. (2023) · Revista Portuguesa de Endocrinologia Diabetes e Metabolismo · doi:10.26497/ao220037
Current Strategies of New Drugs for Diabetes Management
Sarfraz, M., Hafizur, R. M., Ullah, H., Sajid, S., Akhtar, R. W., Noreen, M., Perveen, S., & Khan, M. U. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070005
Sodium-glucose Co-transporter-2 inhibitors: a new era of cardioprotection and renoprotection
Balasubramanian, P., & Inzucchi, S. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00006-1 · Cited by 2
Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research
夏, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142429
Cai, Y., Zou, H., Hu, R., Chen, H., Yang, G., & Gong, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1376446
Cheng, Y., Li, H., Liu, X., Jin, X., Han, J., Du, J., & Xu, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1381248
Treatment of Obesity in Individuals with Type 1 Diabetes
Almehthel, M. S., & Alshehri, A. (2024) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2024.2332
Nakamura, Y., Horie, I., Yano, H., Nomoto, H., Fukui, T., Yuyama, Y., Kawamura, T., Ueda, M., Yamamoto, A., Hirota, Y., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13061287 · Cited by 4
Kugathasan, L., Ragi, N., Debnath, S., Sridhar, V. S., Maity, S., Feng, T., Treviño, E., Perkins, B. A., Cherney, D. Z. I., & Sharma, K. (2025) · Physiological Reports · doi:10.14814/phy2.70465 · Cited by 3
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology
Mottl, A. K., Sawinski, D. L., & Bjornstad, P. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.10.022
Chen, H., Lin, Z., Liu, Z., Li, S., Xue, P., Wei, K., Zhang, M., Cui, J., Liu, W., & Wang, N. (2026) · PeerJ · doi:10.7717/peerj.21087
“Second, leave-one-out analysis revealed that only three outcomes (eGFR, urinary ACR, and diabetic eye disorders) changed from non-significant to significant after removal of individual study ( Buse et al., 2018 ; Dandona et al., 2018 ; Garg et al., 2017 ).”
InfluentialDifferential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Aktürk, H. K. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.005
Ambalavanan, J., Bhasin, K., & Shah, V. N. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.013
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.007
Hughes, M. S., & Pasquel, F. J. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.015
Guanoliquin, K. P. D. L. C., Juca, D. C. S., Alcocer, Y. P., & Cuadrado, S. P. A. (2026) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20262193
Timmons, J. G., Ghanim, H., Boyle, J. G., Greenlaw, N., Chaudhuri, A., Batra, M., Lindsay, R. S., Jolly, L., Bonner, C., McConnachie, A., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71076
Targeting kidney disease in type 1 diabetes: progress and promise
Muskiet, M. H. A., & Cherney, D. Z. I. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2714265
The Diabetes Technology Timeline
Sriravindrarajah, A., Forner, P. M., & SNAITH, J. R. (2026) · Springer eBooks · doi:10.1007/978-3-032-24854-1_1
Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications
Bloomgarden, Z. T. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70427
“Sotagli fl ozin improved glycemia, weight, and insulin dose but increased DKA, as well as being associated with genital fungal infections and diarrhea 43 .”
Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis
Yang, R., Cho, K., Petersen, M. C., Jones, K. E., Patti, G. J., McGill, J. B., & Adamson, S. E. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71390
Metadata
- Authors
- Buse, J. B., Garg, S. K., Rosenstock, J., Bailey, T. S., Banks, P., Bode, B. W., Danne, T., Kushner, J. A., Lane, W. S., Lapuerta, P., McGuire, D. K., Peters, A. L., Reed, J., Sawhney, S., & Strumph, P.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- University of Colorado Anschutz (US)
- Dallas Diabetes Research Center (US)
- AMCR Institute (US)
- Lexicon Pharmaceuticals (United States) (US)
- Emory University (US)
- Medizinische Hochschule Hannover (DE)
- Baylor College of Medicine (US)
- Mountain Diabetes and Endocrine Center (US)
- The University of Texas Southwestern Medical Center (US)
- University of Southern California (US)
- Endocrine Research Solutions (United States) (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-06-24
- Volume
- 41
- Issue
- 9
- Pages
- 1970-1980
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6105319
- OpenAlex
- W2809153459
- Cited by
- 234
- References
- 41
- Citations by year
- 2026: 19 · 2025: 27 · 2024: 24 · 2023: 26 · 2022: 16 · 2021: 22 · 2020: 39 · 2019: 49 · 2018: 12
- FWCI
- 24.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (UL1TR001111, UL1TR002489)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- sotagliflozin, type 1 diabetes, glycemic control, HbA1c, weight loss, insulin dose reduction, diabetes treatment satisfaction, genital mycotic infections, diarrhea, diabetic ketoacidosis, adults with type 1 diabetes, drug safety and efficacy
- MeSH terms
- Adult, Aged, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycosides, Glycated Hemoglobin, Humans, Hypoglycemia, Insulin, Insulin Infusion Systems, Male, Middle Aged, North America, Weight Loss, Diabetic Ketoacidosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.